Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumour × tislelizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 54 Carcinoma, Hepatocellular 38 Stomach Neoplasms 30 Colorectal Neoplasms 30 Esophageal Squamous Cell Carcinoma 21 Squamous Cell Carcinoma of Head and Neck 16 Neoplasm Metastasis 13 Esophageal Neoplasms 13 Advanced Solid Tumor 12 Lung Neoplasms 11 Head and Neck Neoplasms 11 Triple Negative Breast Neoplasms 9 Small Cell Lung Carcinoma 9 Nasopharyngeal Carcinoma 9 Recurrence 8 Rectal Neoplasms 8 Neoplasms 8 Colonic Neoplasms 8 Cholangiocarcinoma 8 Uterine Cervical Neoplasms 7 Pancreatic Neoplasms 7 Melanoma 7 Solid Tumor 5 Lymphoma 5 Hodgkin Disease 5 Carcinoma, Transitional Cell 5 Advanced Solid Tumors 5 Urinary Bladder Neoplasms 4 Sarcoma 4 Lymphoma, Extranodal NK-T-Cell 4

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡